Celularity Inc. (NASDAQ:CELU) Sees Significant Growth in Short Interest

Celularity Inc. (NASDAQ:CELU) saw a significant increase in short interest in the month of March. As of March 31st, there was short interest totalling 415,800 shares, an increase of 7.1% from the March 15th total of 388,300 shares. Approximately 3.9% of the company’s stock are short sold. Based on an average daily trading volume, of 253,600 shares, the days-to-cover ratio is presently 1.6 days.

Celularity Stock Performance

NASDAQ CELU opened at $4.20 on Tuesday. The company has a fifty day moving average of $4.83 and a 200 day moving average of $3.26. Celularity has a 1 year low of $1.59 and a 1 year high of $8.90.

Institutional Inflows and Outflows

A number of large investors have recently modified their holdings of the company. BlackRock Inc. grew its stake in Celularity by 342.3% during the 3rd quarter. BlackRock Inc. now owns 3,471,134 shares of the company’s stock valued at $8,018,000 after acquiring an additional 2,686,262 shares in the last quarter. Vanguard Group Inc. increased its holdings in shares of Celularity by 64.7% during the 3rd quarter. Vanguard Group Inc. now owns 2,985,795 shares of the company’s stock worth $6,897,000 after buying an additional 1,172,900 shares during the last quarter. State Street Corp increased its holdings in shares of Celularity by 197.1% during the 3rd quarter. State Street Corp now owns 609,015 shares of the company’s stock worth $1,407,000 after buying an additional 404,042 shares during the last quarter. Renaissance Technologies LLC increased its holdings in shares of Celularity by 242.2% during the 2nd quarter. Renaissance Technologies LLC now owns 274,406 shares of the company’s stock worth $146,000 after buying an additional 194,206 shares during the last quarter. Finally, Bank of New York Mellon Corp boosted its position in shares of Celularity by 632.1% during the 3rd quarter. Bank of New York Mellon Corp now owns 191,134 shares of the company’s stock worth $442,000 after purchasing an additional 165,028 shares during the period. Institutional investors and hedge funds own 19.02% of the company’s stock.

Celularity Company Profile

Celularity Inc, a clinical-stage biotechnology company, develops off-the-shelf placental-derived allogeneic cell therapies for the treatment of cancer, immune, and infectious diseases. It operates through three segments: Cell Therapy, Degenerative Disease, and BioBanking. The company's lead therapeutic programs include CYCART-19, an allogeneic CAR-T cell for the treatment of non-Hodkin's lymphoma (NHL) and mantle cell lymphoma (MCL); CYNK-001, an allogeneic unmodified natural killer cell that is in Phase I/II clinical trial for the treatment of acute myeloid leukemia (AML); and APPL-001, a genetically modified placental-derived mesenchymal-like adherent stromal cell for the treatment of Crohn's disease.